A61K 2239/50
Colon
A61K2239/50 (Colon) appears on 180 US grants and 398 published applications in this corpus.
Search patents in A61K- Granted patents
- 180
- Published applications
- 398
- Assignees
- 241
- Inventors
- 810
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1994 | 1 | 0 |
| 1995 | 1 | 0 |
| 1996 | 0 | 0 |
| 1997 | 2 | 0 |
| 1998 | 2 | 0 |
| 1999 | 1 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 1 |
| 2002 | 1 | 3 |
| 2003 | 3 | 6 |
| 2004 | 1 | 6 |
| 2005 | 0 | 5 |
| 2006 | 4 | 6 |
| 2007 | 0 | 9 |
| 2008 | 7 | 2 |
| 2009 | 2 | 4 |
| 2010 | 3 | 4 |
| 2011 | 3 | 6 |
| 2012 | 3 | 4 |
| 2013 | 3 | 6 |
| 2014 | 2 | 6 |
| 2015 | 4 | 5 |
| 2016 | 6 | 13 |
| 2017 | 3 | 11 |
| 2018 | 6 | 10 |
| 2019 | 5 | 25 |
| 2020 | 4 | 46 |
| 2021 | 10 | 38 |
| 2022 | 24 | 44 |
| 2023 | 13 | 46 |
| 2024 | 27 | 39 |
| 2025 | 28 | 28 |
| 2026 | 11 | 25 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Chimeric antigen receptor for treatment of cancer29 Sep 2026US 12,747,278 B2Industry-Academic Cooperation Foundation, Yonsei University
- Presenting cell and use thereof in cell therapy11 Aug 2026US 12,702,708 B2Innovative Cellular Therapeutics Holdings, Ltd.
- Fusion constructs and methods of using thereof11 Aug 2026US 12,703,747 B2Precigen, Inc.
- Anti-glypican-1-immunizing antigen receptor4 Aug 2026US 12,698,339 B2Iwate Medical University
- Chimeric antigen receptor T cells and methods of use thereof30 Jun 2026US 12,668,777 B2Augusta University Research Institute, Inc.
- Chimeric antigen receptor t cells and methods of use thereof8 Oct 2026US 2026/0308521 A1Augusta University Research Institute, Inc.
- Anti-btn3a antibodies and their use in treating cancer or infectious disorders20 Aug 2026US 2026/0242480 A1Centre National de la Recherche Scientifique (CNRS)
- Anti-btn3a antibodies and their use in treating cancer or infectious disorders20 Aug 2026US 2026/0242483 A1Centre National de la Recherche Scientifique (CNRS)
- Mir-326 for the treatment of cancer13 Aug 2026US 2026/0234615 A1FundacióN Para La InvestigacióN BioméDica Del Hospital Universitario RamóN Y Cajal
- Recombinant immune cell-based cell therapeutic agent for treating cancer via polyclonal expansion of tumor-infiltrating t cell in tumor6 Aug 2026US 2026/0224615 A1Korea Advanced Institute of Science and Technology
Most cited
By later US patents
- Universal anti-tag chimeric antigen receptor-expressing T cells and methods of treating cancer87US 9,233,125 B2University of Maryland, Baltimore · 2016
- In situ immunization53US 7,763,243 B2Roger Williams Medical Center · 2010
- Human cytotoxic T-lymphoctye epitope and its agonist eptiope from the non-variable number of tandem repeat sequence of MUC-139US 7,999,071 B2The United States of America, as represented by the Secretary, Department of Health and Human Services · 2011
- Method for expansion of tumour-reactive T-lymphocytes for immunotherapy of patients with cancer38US 8,206,702 B2SentoClone International AB · 2012
- Anti-tumor T cell immunity induced by high dose radiation35US 9,545,444 B2The Board of Trustees of the Leland Stanford Junior University · 2017